Toronto (pcJ News Brifes) – Helix BioPharma Corp. (TSX/FSE: HBP), an immuno-oncology company developing innovative drug candidates for the prevention and treatment of cancer, has closed a private placement of 683,333 units at $1.20 per unit for gross proceeds of approximately $820,000.
Each unit is comprised of one common share and one common share purchase warrant. Each common share purchase warrant will entitle the holder to purchase one common share at an exercise price of $1.50 and have an expiry of five years from the date of issuance.
Helix BioPharma intends to use the net proceeds of the private placement for working capital and research and development activities.
ACM Alpha Management Consulting Est. provided financial advisory services to Helix in connection with the private placement.
Helix BioPharma is a clinical-stage biopharmaceutical company developing unique therapies in the field of immuno-oncology, based on its proprietary technological platform DOS47.
photo credit: Helix BioPharma